4314-35-6

Usage

Uses

Used in Pharmaceutical Research:
(1Z)-2,2,2-trifluoro-N'-hydroxyethanimidamide (SALTDATA: FREE) is used as a reagent in pharmaceutical research for its unique properties and reactivity, contributing to the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (1Z)-2,2,2-trifluoro-N'-hydroxyethanimidamide (SALTDATA: FREE) is utilized as a key intermediate, enabling the creation of complex organic molecules with enhanced stability and functionality.
Used in Agrochemicals:
(1Z)-2,2,2-trifluoro-N'-hydroxyethanimidamide (SALTDATA: FREE) is employed in the design and synthesis of agrochemicals, where its trifluoro substitution and hydroxyethanimidamide group provide advantages in the development of effective and stable pesticides and other agricultural chemicals.
Used in Materials Science:
In materials science, (1Z)-2,2,2-trifluoro-N'-hydroxyethanimidamide (SALTDATA: FREE) is used as a building block for the synthesis of novel materials with improved properties, such as enhanced stability, reactivity, or specific functional characteristics.

Upstream product

• 815-03-2 (trifluoroacetyl)hydroximoyl chloride 
• 353-85-5 trifluoroacetonitrile 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 88326-84-5 2,2,2-Trifluoroacetamide O-Benzoyloxime 
• 1414570-79-8 4-methyl-1-phenyl-3-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-5-amine 
• 1430746-01-2 5-((1R,3s,5S)-3-((1r,4R)-4-(4-(methylsulfonyl)phenoxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octan-8-yl)-3-(trifluoromethyl)-1,2,4-oxadiazole 
• 1430746-06-7 5-((1R,3s,5S)-3-((1r,4R)-4-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)cyclohexyloxy)-8-azabicyclo[3.2.1]octan-8-yl)-3-(trifluoromethytl)-1,2,4-oxadiazole 
• 1437800-29-7 1-(2,5-difluoro-4-(methylsulfonyl)benzyl)-3-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yl)imidazolidin-2-one 
• 1415818-07-3 (1r,4r)-4-(1-(3-(trifluoromethyl)-1,2,4-oxadiazol-5-yl)piperidin-4-yloxy)cyclohexanol 
• 100442-49-7 5-(chloromethyl)-3-(trifluoro-methyl)-1,2,4-oxadiazole 
• 1287685-44-2 5-((4-(2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)piperidin-1-yl)methyl)-3-(trifluoromethyl)-1,2,4-oxadiazole 

Relevant academic research and scientific papers

METHOD FOR PRODUCING OXADIAZOLE DERIVATIVE SUBSTITUTED WITH AMINO GROUP

PROBLEM TO BE SOLVED: To provide an intermediate and a production method of an oxadiazole derivative substituted with an amino group, the derivative having NPY Y5 receptor antagonism. SOLUTION: Provided is an intermediate which is a salt of a compound represented by formula (I) and one basic compound selected from a substituted or unsubstituted imidazole, substituted triazole, substituted pyrazole, substituted pyrrole, substituted or unsubstituted bezimidazole, substituted benzotriazole, and substituted benzopyrazole. Also provided is a method for producing an oxadiazole derivative substituted with an amino group, comprising reacting the salt with a halogenating agent or a base, if desired, in the presence of a basic compound which forms the salt, the derivative having NPY Y5 receptor antagonism. SELECTED DRAWING: None COPYRIGHT: (C)2018,JPOandINPIT

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14′, R15, R15′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which ca

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

N-BICYCLIC ARYL,N'-PYRAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

A facile synthesis of 3-trifluoromethyl-1,2,4-oxadiazoles from cyanamides

A safe and facile method for the formation of 3-trifluoromethyl-5-amino-1, 2,4-oxadiazoles, via a reversed addition of hydroxylamine to cyanamides, is reported. This two-pot procedure is suitable to scale-up and avoids the hazards associated with trifluor